Debate Series - Estro-events.org

posTErs
Posters
Page 426 PROgRammE & ExhibiTiOn guidE • WCB 2012
abS. numbER
> Ultrasound-CT fusion compared to MR-CT fusion for post implant
dosimetry in permanent prostate brachytherapy
J.M. Crook (Canada), C. Araujo, M. Gaztanaga, D. Batchelar, D.M. Bowes PO-194
> Biochemical results for high risk prostate cancer after
high-dose-rate brachytherapy with external radiotherapy
E. Arrojo Alvarez (Spain), P.J. Prada, L. Méndez, J. Fernández,
H. González, I. Jiménez PO-195
> Natural dose volume histogram: relation with volume of target
and seeds per needle in permanent prostate implants
R. Martinez Cobo (Spain), E. Rivin del Campo, J.M. Roldán Arjona,
A. Palacios Eito PO-196
> High definition customised brachytherapy for prostate cancer based
on transperineal sector mapping biopsies
S.L. Morris (United Kingdom), M. McGovern, R. Tsung, S.L. Aldridge,
B. Challacombe, R.B. Beaney, R.B. Popert PO-197
> Comparison of treatment plan parameters in brachytherapy of
prostate cancer in different schedules
M. Kanikowski (Poland), J. Skowronek, A. Chichel PO-198
> Prostate volume-based nomograms for prostate seed implants:
customizing for a range of seed activities
S.J. Gardner (USA), K.L. Chapman, A.P. Dicker, T.N. Showalter,
L.A. Doyle PO-199
> V150 predicts erectile outcome in patients undergoing
low-dose-rate (LDR) brachytherapy alone for prostate cancer
M.A. Kollmeier (USA), L.M. Scala, D. Kunaprayoon, N. Mathur,
G. Cohen, X. Pei, Z. Zhang, J. Mulhall, B. Cox, M.J. Zelefsky PO-200
> Institutional analysis of outcomes for stages T1-T2 prostate
cancer treated with brachytherapy
A. Soares (Portugal), L. Trigo, L. Carvalho, A. Pereira, T. Viterbo,
R. Henrique, J. Matos, C. Castro, A. Oliveira, J. Oliveira PO-201
Posters
abS. numbER
> Long term results with multimodality radiotherapy
(3D, IGRT, LDRBT, HDRBT) in prostate adenocarcinoma
S. Rodríguez Villalba (Spain), M. Santos Ortega, M. Deppiagio,
J. Pérez Calatayud, J. Richart, F. Ballester PO-202
> Rectum preservation by bolus hyaluronan injection into
peri/para rectal space during HDR-BT of prostate cancer
K. Kishi (Japan), M. Sato, Y. Noda, T. Sonomura, S. Shirai, R. Yamada PO-203
> LDRBT in low risk prostate adenocarcinoma. 145 gy. vs 160 gy.
Long term results and toxicity
M. Depiaggio (Spain), M. Santos, S. Rodriguez, J. Richart,
J. Perez-Calatayud, F. Ballester PO-204
> Potential benefit of adaptive treatment planning for
PDR prostate brachytherapy
A.M. Dinkla (The Netherlands), B.R. Pieters, P. Meijnen, C. Koedooder,
N. van Wieringen, R. van der Laarse, J.N. van der Grient, A. Bel PO-205
> Acute toxicity of single fraction boost with HDR BT after
hypofractionated EBRT for locally advanced prostate cancer
K. Murata (Japan), H. Katoh, H. Ishikawa, T. Kaminuma, T. Ebara,
M. Miyakubo, H. Matsui, K. Itoh, K. Suzuki, T. Nakano PO-206
> Rectal bleeding in patients treated with HDR brachytherapy
combined with EBRT for prostate cancer
S. Kariya (Japan), I. Yamasaki, S. Ashida, T. Shuin, A. Nishioka,
Y. Ogawa PO-207
> Quality of HDR brachytherapy of favorable localized prostate
cancer and number of implanted needles
E. Slobina (Belarus), D. Kozlovsky, A. Soroka, Y. Ezhgurova PO-208
> Rescue treatment in prostate cancer for local relapse after radiotherapy
with high-dose rate brachytherapy
K. Quispe Santibáñez (Spain), E. Martínez Pérez, J. Pera Fàbregas,
C. Gutiérrez Miguélez, F. Pino Sorroche, M. Ventura Bujalance, J.F. Suárez Novo,
A.M. Boladeras Inglada, F. Ferrer González, F. Guedea Edo PO-209
WCB 2012 • PROgRammE & ExhibiTiOn guidE Page 427
posTErs
WCB